Livingstone, Ann http://orcid.org/0000-0002-6836-0382
Dempsey, Kathy http://orcid.org/0000-0003-4945-0857
Stockler, Martin R. http://orcid.org/0000-0003-3793-8724
Howard, Kirsten
Long, Georgina V. http://orcid.org/0000-0001-8894-3545
Carlino, Matteo S.
Menzies, Alexander M. http://orcid.org/0000-0001-5183-7562
Morton, Rachael L. http://orcid.org/0000-0001-7834-0572
Article History
Received: 11 May 2021
Accepted: 1 September 2021
First Online: 10 September 2021
Declarations
:
: The Sydney Local Health District Human Research Ethics Committee (HREC/18/RPAH/736) granted ethics approval. Participants provided informed written consent, with the Declaration of Helsinki underpinning this study [CitationRef removed].
: Not applicable as this manuscript does not reveal any identifiable participant information.
: AL, KD, KH and RLM have no conflicts of interest to declare. MRS received institutional research support from Amgen, Astellas, AstraZeneca, Bayer, Bionomics, Bristol-Myers Squibb (BMS), Celgene, Medivation, Merck Sharpe & Dohme (MSD), Pfizer, Roche, Sanofi and Tilray, but does not sit on any advisory boards. AMM has served on advisory boards for BMS, MSD, Novartis, Pierre-Fabre, Qbiotics and Roche. GVL is a consultant advisor for Aduro Biotech, Amgen, Array Biopharma, Boehringer Ingelheim, BMS, Hexel AG, Highlight Therapeutics SL, MSD, Novartis, Pierre-Fabre, QBiotics, Regeneron Pharmaceuticals, SkylineDX B.V., and Specialised Therapeutics Australia. MSC has served on advisory boards for Amgen, BMS, Eisai, Ideaya, MSD, Nektar, Novartis, Oncosec, Pierre-Fabre, Qbiotics, Regeneron, Roche, and Sanofi, and received honoraria from BMS, MSD, and Novartis.